Backlash grows against anti-flu drug's clinical efficacy and cost

By Paul Dinsdale2000-11-30T00:00:00

Senior influenza experts have joined a growing backlash against the anti-flu drug Relenza which they fear could have potentially serious financial effects on the NHS and they claim is of unproven clinical effectiveness.

You need to be a subscriber to read more

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

All HSJ news by sector, topic & region
Breaking News announcements
App for mobile and offline reading
Comment and Daily Insights newsletters
Regional roundup newsletters
10 expert briefings every fortnight (Premium only)
Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)

to HSJ

Already a subscriber? Sign into your account here